These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 36338164)

  • 61. The Added Value of Coronary Calcium Score in Predicting Cardiovascular Events in Familial Hypercholesterolemia.
    Gallo A; Pérez de Isla L; Charrière S; Vimont A; Alonso R; Muñiz-Grijalvo O; Díaz-Díaz JL; Zambón D; Moulin P; Bruckert E; Mata P; Béliard S;
    JACC Cardiovasc Imaging; 2021 Dec; 14(12):2414-2424. PubMed ID: 34274263
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The retardation of progression, stabilization, and regression of coronary and carotid atherosclerosis by low-density lipoprotein apheresis in patients with familial hypercholesterolemia.
    Koga N
    Ther Apher; 1997 Aug; 1(3):260-70. PubMed ID: 10225750
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Familial Hypercholesterolemia and Lipoprotein(a): A Gordian Knot in Cardiovascular Prevention.
    Koutsogianni AD; Adamidis PS; Barkas F; Liberopoulos E; Su TC; Yamashita S; Liamis G; Rizzo M
    Metabolites; 2022 Nov; 12(11):. PubMed ID: 36355148
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Impact of LDLR and PCSK9 pathogenic variants in Japanese heterozygous familial hypercholesterolemia patients.
    Hori M; Ohta N; Takahashi A; Masuda H; Isoda R; Yamamoto S; Son C; Ogura M; Hosoda K; Miyamoto Y; Harada-Shiba M
    Atherosclerosis; 2019 Oct; 289():101-108. PubMed ID: 31491741
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [The role of PCSK9-inhibitors and of lipoprotein apheresis in the treatment of homozygous and severe heterozygous familial hypercholesterolemia: A rivalry, or are things quite different?].
    Bláha V; Bláha M; Lánská M; Havel E; Vyroubal P; Zadák Z; Žák P
    Vnitr Lek; 2018; 64(1):43-50. PubMed ID: 29498875
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.
    Miname MH; Santos RD
    Prog Cardiovasc Dis; 2019; 62(5):414-422. PubMed ID: 31669498
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Genetic testing for familial hypercholesterolemia: Impact on diagnosis, treatment and cardiovascular risk.
    Lee S; Akioyamen LE; Aljenedil S; Rivière JB; Ruel I; Genest J
    Eur J Prev Cardiol; 2019 Aug; 26(12):1262-1270. PubMed ID: 30755017
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The different relations of PCSK9 and Lp(a) to the presence and severity of atherosclerotic lesions in patients with familial hypercholesterolemia.
    Cao YX; Liu HH; Sun D; Jin JL; Xu RX; Guo YL; Wu NQ; Zhu CG; Li S; Zhang Y; Sun J; Li JJ
    Atherosclerosis; 2018 Oct; 277():7-14. PubMed ID: 30170223
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Assessment of coronary atherosclerosis in patients with familial hypercholesterolemia by coronary computed tomography angiography.
    Tada H; Kawashiri MA; Okada H; Teramoto R; Konno T; Yoshimuta T; Sakata K; Nohara A; Inazu A; Kobayashi J; Mabuchi H; Yamagishi M; Hayashi K
    Am J Cardiol; 2015 Mar; 115(6):724-9. PubMed ID: 25618577
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Nonpharmacological lipoprotein apheresis reduces arterial inflammation in familial hypercholesterolemia.
    van Wijk DF; Sjouke B; Figueroa A; Emami H; van der Valk FM; MacNabb MH; Hemphill LC; Schulte DM; Koopman MG; Lobatto ME; Verberne HJ; Fayad ZA; Kastelein JJ; Mulder WJ; Hovingh GK; Tawakol A; Stroes ES
    J Am Coll Cardiol; 2014 Oct; 64(14):1418-26. PubMed ID: 25277610
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
    Kazi DS; Moran AE; Coxson PG; Penko J; Ollendorf DA; Pearson SD; Tice JA; Guzman D; Bibbins-Domingo K
    JAMA; 2016 Aug; 316(7):743-53. PubMed ID: 27533159
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Prevalence of familial hypercholesterolemia in patients with acute coronary syndrome in Japan: Results of the EXPLORE-J study.
    Harada-Shiba M; Ako J; Arai H; Hirayama A; Murakami Y; Nohara A; Ozaki A; Uno K; Nakamura M
    Atherosclerosis; 2018 Oct; 277():362-368. PubMed ID: 30270072
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Non-coronary atherosclerotic cardiovascular disease in patients with familial hypercholesterolaemia.
    Anagnostis P; Vaitsi K; Mintziori G; Goulis DG; Mikhailidis DP
    Curr Med Res Opin; 2020 May; 36(5):731-740. PubMed ID: 32096673
    [No Abstract]   [Full Text] [Related]  

  • 74. Lipoprotein metabolism in familial hypercholesterolemia: Serial assessment using a one-step ultracentrifugation method.
    Tada H; Kawashiri MA; Nohara A; Inazu A; Mabuchi H; Yamagishi M; Hayashi K
    Pract Lab Med; 2015 Apr; 1():22-27. PubMed ID: 28932795
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry.
    deGoma EM; Ahmad ZS; O'Brien EC; Kindt I; Shrader P; Newman CB; Pokharel Y; Baum SJ; Hemphill LC; Hudgins LC; Ahmed CD; Gidding SS; Duffy D; Neal W; Wilemon K; Roe MT; Rader DJ; Ballantyne CM; Linton MF; Duell PB; Shapiro MD; Moriarty PM; Knowles JW
    Circ Cardiovasc Genet; 2016 Jun; 9(3):240-9. PubMed ID: 27013694
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The molecular genetic basis and diagnosis of familial hypercholesterolemia in Denmark.
    Jensen HK
    Dan Med Bull; 2002 Nov; 49(4):318-45. PubMed ID: 12553167
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The Achievement of Non-high-density Lipoprotein Cholesterol Target in Patients with Very High Atherosclerotic Cardiovascular Disease Risk Stratified by Triglyceride Levels Despite Statin-controlled Low-density Lipoprotein Cholesterol.
    Al-Sabti H; Al-Hinai AT; Al-Zakwani I; Al-Hashmi K; Al Mahmeed W; Arafah M; Shehab A; Al Tamimi O; Al Awadhi M; Al Herz S; Al Anazi F; Al Nemer K; Metwally O; Alkhadra A; Fakhry M; Elghetany H; Medani AR; Yusufali AH; Al Jassim O; Al Hallaq O; Baslaib FOAS; Amin H; Al-Waili K; Al-Rasadi K
    Oman Med J; 2022 Mar; 37(2):e367. PubMed ID: 35449790
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Risk of Premature Atherosclerotic Disease in Patients With Monogenic Versus Polygenic Familial Hypercholesterolemia.
    Trinder M; Li X; DeCastro ML; Cermakova L; Sadananda S; Jackson LM; Azizi H; Mancini GBJ; Francis GA; Frohlich J; Brunham LR
    J Am Coll Cardiol; 2019 Jul; 74(4):512-522. PubMed ID: 31345425
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group.
    Mabuchi H; Koizumi J; Shimizu M; Kajinami K; Miyamoto S; Ueda K; Takegoshi T
    Am J Cardiol; 1998 Dec; 82(12):1489-95. PubMed ID: 9874053
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The tertiary hospital laboratory; a novel avenue of opportunistic screening of familial hypercholesterolemia.
    Mirzaee S; Choy KW; Doery JCG; Zaman S; Cameron JD; Nasis A
    Int J Cardiol Heart Vasc; 2019 Jun; 23():100354. PubMed ID: 31080874
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.